354 related articles for article (PubMed ID: 28601421)
41. Effectiveness of Pneumococcal Conjugate Vaccines of Different Valences Against Invasive Pneumococcal Disease Among Children in Taiwan: A Nationwide Study.
Su WJ; Lo HY; Chang CH; Chang LY; Chiu CH; Lee PI; Lu CY; Hsieh YC; Lai MS; Lin TY
Pediatr Infect Dis J; 2016 Apr; 35(4):e124-33. PubMed ID: 26974752
[TBL] [Abstract][Full Text] [Related]
42. Long-term Impact of Pneumococcal Conjugate Vaccines on Invasive Disease and Pneumonia Hospitalizations in Indigenous and Non-Indigenous Australians.
Meder KN; Jayasinghe S; Beard F; Dey A; Kirk M; Cook H; Strachan J; Sintchenko V; Smith H; Giele C; Howden B; Krause V; Mcintyre P
Clin Infect Dis; 2020 Jun; 70(12):2607-2615. PubMed ID: 31388670
[TBL] [Abstract][Full Text] [Related]
43. Streptococcus pneumoniae serotype 19A: worldwide epidemiology.
Isturiz R; Sings HL; Hilton B; Arguedas A; Reinert RR; Jodar L
Expert Rev Vaccines; 2017 Oct; 16(10):1007-1027. PubMed ID: 28783380
[TBL] [Abstract][Full Text] [Related]
44. Economic and clinical evaluation of a catch-up dose of 13-valent pneumococcal conjugate vaccine in children already immunized with three doses of the 7-valent vaccine in Italy.
Boccalini S; Azzari C; Resti M; Valleriani C; Cortimiglia M; Tiscione E; Bechini A; Bonanni P
Vaccine; 2011 Nov; 29(51):9521-8. PubMed ID: 22008820
[TBL] [Abstract][Full Text] [Related]
45. Effect of the of 10-valent pneumococcal conjugate vaccine in Nepal 4 years after introduction: an observational cohort study.
Shrestha S; Gurung M; Amatya P; Bijukchhe S; Bose AS; Carter MJ; Gautam MC; Gurung S; Hinds J; Kandasamy R; Kelly S; Khadka B; Maskey P; Mujadidi YF; O'Reilly PJ; Pokhrel B; Pradhan R; Shah GP; Shrestha S; Wahl B; O'Brien KL; Knoll MD; Murdoch DR; Kelly DF; Thorson S; Voysey M; Pollard AJ;
Lancet Glob Health; 2022 Oct; 10(10):e1494-e1504. PubMed ID: 36113533
[TBL] [Abstract][Full Text] [Related]
46. Persistent Circulation of Vaccine Serotypes and Serotype Replacement After 5 Years of Infant Immunization With 13-Valent Pneumococcal Conjugate Vaccine in the United Kingdom.
Kandasamy R; Voysey M; Collins S; Berbers G; Robinson H; Noel I; Hughes H; Ndimah S; Gould K; Fry N; Sheppard C; Ladhani S; Snape MD; Hinds J; Pollard AJ
J Infect Dis; 2020 Mar; 221(8):1361-1370. PubMed ID: 31004136
[TBL] [Abstract][Full Text] [Related]
47. Pneumonia hospitalization after introduction of pneumococcal conjugate vaccine in Japan: Descriptive study using a nationwide claims database.
Yanai T; Yoshida S; Takeuchi M; Kawakami K
Vaccine; 2023 Jun; 41(29):4313-4318. PubMed ID: 37286407
[TBL] [Abstract][Full Text] [Related]
48. Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trial.
Cutts FT; Zaman SM; Enwere G; Jaffar S; Levine OS; Okoko JB; Oluwalana C; Vaughan A; Obaro SK; Leach A; McAdam KP; Biney E; Saaka M; Onwuchekwa U; Yallop F; Pierce NF; Greenwood BM; Adegbola RA;
Lancet; 2005 Mar 26-Apr 1; 365(9465):1139-46. PubMed ID: 15794968
[TBL] [Abstract][Full Text] [Related]
49. Pneumonia hospitalizations of children aged <2 years in Poland before (2013-2016) and after (2017-2018) universal mass vaccination with 10-valent pneumococcal non-typeable
Bhavsar A; Zaryczański J; Wasilewska A; Saragoussi D; Devadiga R; Colby C; Bahar E; Wysocki J
Hum Vaccin Immunother; 2022 Nov; 18(6):2128566. PubMed ID: 36239615
[TBL] [Abstract][Full Text] [Related]
50. [Effect of the Pneumococcal Conjugated Vaccines on Burden of all Cause Pneumonia, Bacterial Pneumonia and Empyema in Children].
Tsakir C; Özdemir H; Arga G; Konca HK; Çakmak Taşkın E; Öcal D; Çiftçi E; İnce E
Mikrobiyol Bul; 2022 Jul; 56(3):466-479. PubMed ID: 35960238
[TBL] [Abstract][Full Text] [Related]
51. Invasive pneumococcal disease incidence in children and adults in France during the pneumococcal conjugate vaccine era: an interrupted time-series analysis of data from a 17-year national prospective surveillance study.
Ouldali N; Varon E; Levy C; Angoulvant F; Georges S; Ploy MC; Kempf M; Cremniter J; Cohen R; Bruhl DL; Danis K
Lancet Infect Dis; 2021 Jan; 21(1):137-147. PubMed ID: 32702302
[TBL] [Abstract][Full Text] [Related]
52. Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark.
Harboe ZB; Valentiner-Branth P; Ingels H; Rasmussen JN; Andersen PH; Bjerre CC; Goldblatt D; Ashton L; Haston M; Konradsen HB; Lambertsen L;
PLoS One; 2013; 8(1):e51460. PubMed ID: 23365635
[TBL] [Abstract][Full Text] [Related]
53. Incidence of invasive pneumococcal disease in children with commercial insurance or Medicaid coverage in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998-2018.
Hu T; Song Y; Done N; Liu Q; Sarpong EM; Lemus-Wirtz E; Signorovitch J; Mohanty S; Weiss T
BMC Public Health; 2022 Sep; 22(1):1677. PubMed ID: 36064378
[TBL] [Abstract][Full Text] [Related]
54. Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice.
Azzari C; Martinón-Torres F; Schmitt HJ; Dagan R
Pediatr Infect Dis J; 2014 Aug; 33(8):858-64. PubMed ID: 24618937
[TBL] [Abstract][Full Text] [Related]
55. Effect and cost-effectiveness of pneumococcal conjugate vaccination: a global modelling analysis.
Chen C; Cervero Liceras F; Flasche S; Sidharta S; Yoong J; Sundaram N; Jit M
Lancet Glob Health; 2019 Jan; 7(1):e58-e67. PubMed ID: 30554762
[TBL] [Abstract][Full Text] [Related]
56. Direct, indirect and total effects of 13-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in children in Navarra, Spain, 2001 to 2014: cohort and case-control study.
Guevara M; Barricarte A; Torroba L; Herranz M; Gil-Setas A; Gil F; Bernaola E; Ezpeleta C; Castilla J;
Euro Surveill; 2016; 21(14):. PubMed ID: 27103428
[TBL] [Abstract][Full Text] [Related]
57. The rise and fall of pneumococcal serotypes carried in the PCV era.
Devine VT; Cleary DW; Jefferies JM; Anderson R; Morris DE; Tuck AC; Gladstone RA; O'Doherty G; Kuruparan P; Bentley SD; Faust SN; Clarke SC
Vaccine; 2017 Mar; 35(9):1293-1298. PubMed ID: 28161425
[TBL] [Abstract][Full Text] [Related]
58. The direct effect of pneumococcal conjugate vaccines on invasive pneumococcal disease in children in the Latin American and Caribbean region (SIREVA 2006-17): a multicentre, retrospective observational study.
Agudelo CI; Castañeda-Orjuela C; Brandileone MCC; Echániz-Aviles G; Almeida SCG; Carnalla-Barajas MN; Regueira M; Fossati S; Alarcón P; Araya P; Duarte C; Sánchez J; Novas M; Toraño-Peraza G; Rodríguez-Ortega M; Chamorro-Cortesi G; Kawabata A; García-Gabarrot G; Camou T; Spadola E; Payares D; Andrade AL; Di Fabio JL; Castañeda E;
Lancet Infect Dis; 2021 Mar; 21(3):405-417. PubMed ID: 32986996
[TBL] [Abstract][Full Text] [Related]
59. Impact of pneumococcal conjugate vaccines on healthcare utilization and direct costs for otitis media in children ≤2 years of age in two Swedish regions.
Edmondson-Jones M; Dibbern T; Hultberg M; Anell B; Medin E; Feng Y; Talarico C
Hum Vaccin Immunother; 2022 Dec; 18(1):1942712. PubMed ID: 34319865
[TBL] [Abstract][Full Text] [Related]
60. Reductions in Childhood Pneumonia Mortality After Vaccination in the United States.
Paternina-Caicedo A; Smith AD; Buchanich J; Garcia-Calavaro C; Alvis-Guzman N; Narvaez J; de Oliveira LH; De la Hoz-Restrepo F
Pediatr Infect Dis J; 2023 Aug; 42(8):723-729. PubMed ID: 37235761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
